Newer, more expensive medications don’t work much better for the chronic inflammatory skin disease known as psoriasis than the standard treatment, a new study indicates. The researchers found that biologics, which can cost upwards of $10,000 a year, were slightly more effective than a standard drug treatment for psoriasis, methotrexate, but that their impact lessened over time.
